{"disease":{"id":"transthyretin-amyloid-cardiomyopathy-attr-cm","name":"transthyretin amyloid cardiomyopathy attr cm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07207811","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05442047","title":"A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06338696","title":"Thailand ATTR-CM Registry","phase":"","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT06260709","title":"A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06393465","title":"Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05210010","title":"A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"Ensho Health Intelligent Systems Inc.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}